Characterisation of a myocardial infarction biomarker, brain-type natriuretic peptide, as a biomarker of cognitive dysfunction

    Authors

    Keywords

    natriuretic peptides, brain natriuretic peptide, biomarker of myocardial infarction, Alzheimer’s disease

    DOI

    https://doi.org/10.15836/ccar2018.435

    Full Text

    Introduction: Presence of a cardiovascular disorder may contribute to poor cognitive aging and Alzheimer’s disease (AD)-type cognitive decline. AD is the most prevalent age-related neurodegenerative disease which is prominently characterised by progressive loss of cognitive abilities for which specific and sensitive biomarkers and disease-modifying therapies are lacking. ( 1 - 3 ) Brain-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are the most important humoral indicators of cardiac dysfunction and heart failure, and their level in blood is proportional to the degree of myocardial function failure. In an effort to identify key biomarker(s) of AD, from an easily accessible biological fluid, such as blood, that would aid in early diagnosing and/or monitoring of a progression of AD, plasma levels of BNP were examined in subjects with differing cognitive abilities. Materials and Methods: Human subjects were recruited for the European Union-funded AddNeuroMed biomarker project through medical centres based in several countries (UK, Finland, Italy, Greece and Poland). BNP levels in the subjects’ plasma samples were measured using Slow Off-rate Aptamer (SOMAmer)-based capture array called SOMAscan (SomaLogic, Inc., CO, USA). BNP measurements from the AddNeuroMed subjects were obtained from the Synapse Data Platform which is hosted by Sage Bionetworks ( https://www.synapse.org ). Results: Plasma BNP levels were compared between two groups of subjects: 1) healthy subjects (N=189), and 2) subjects diagnosed with probable Alzheimer’s-type dementia (N=308). Our analysis shows that subjects diagnosed with probable AD have significantly lower BNP levels (2986.82 ± 238.82) compared to healthy controls (3041.98 ± 236.67) (U = 24935.00, Z = -2.68, p = 0.007). Conclusions: Decreased plasma levels of an established cardiovascular biomarker, BNP, as measured by a novel technology termed SOMAscan, appear to associate with declining brain health. Our results warrant further investigations into a role of BNP in AD and they have implications for a wider population as they are related to a research cohort that consisted of subjects who were recruited from a wider geographic area (several European countries).

    Cardiologia Croatica
    Back to search

    Characterisation of a myocardial infarction biomarker, brain-type natriuretic peptide, as a biomarker of cognitive dysfunction

    Extended Abstract
    Issue11-12
    Published
    Pages435
    PDF via DOIhttps://doi.org/10.15836/ccar2018.435
    natriuretic peptides
    brain natriuretic peptide
    biomarker of myocardial infarction
    Alzheimer’s disease

    Authors

    Edin Begic*ORCID
    Suncica HadzidedicORCID
    Ajla KulaglicORCID
    Belma Ramic-BrkicORCID
    Zijo BegicORCID
    Mirsada CausevicORCID

    Full Text

    Introduction: Presence of a cardiovascular disorder may contribute to poor cognitive aging and Alzheimer’s disease (AD)-type cognitive decline. AD is the most prevalent age-related neurodegenerative disease which is prominently characterised by progressive loss of cognitive abilities for which specific and sensitive biomarkers and disease-modifying therapies are lacking. ( 1 - 3 ) Brain-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are the most important humoral indicators of cardiac dysfunction and heart failure, and their level in blood is proportional to the degree of myocardial function failure. In an effort to identify key biomarker(s) of AD, from an easily accessible biological fluid, such as blood, that would aid in early diagnosing and/or monitoring of a progression of AD, plasma levels of BNP were examined in subjects with differing cognitive abilities. Materials and Methods: Human subjects were recruited for the European Union-funded AddNeuroMed biomarker project through medical centres based in several countries (UK, Finland, Italy, Greece and Poland). BNP levels in the subjects’ plasma samples were measured using Slow Off-rate Aptamer (SOMAmer)-based capture array called SOMAscan (SomaLogic, Inc., CO, USA). BNP measurements from the AddNeuroMed subjects were obtained from the Synapse Data Platform which is hosted by Sage Bionetworks ( https://www.synapse.org ). Results: Plasma BNP levels were compared between two groups of subjects: 1) healthy subjects (N=189), and 2) subjects diagnosed with probable Alzheimer’s-type dementia (N=308). Our analysis shows that subjects diagnosed with probable AD have significantly lower BNP levels (2986.82 ± 238.82) compared to healthy controls (3041.98 ± 236.67) (U = 24935.00, Z = -2.68, p = 0.007). Conclusions: Decreased plasma levels of an established cardiovascular biomarker, BNP, as measured by a novel technology termed SOMAscan, appear to associate with declining brain health. Our results warrant further investigations into a role of BNP in AD and they have implications for a wider population as they are related to a research cohort that consisted of subjects who were recruited from a wider geographic area (several European countries).